cobas® TaqScreen West Nile Virus Test

Early detection of WNV

cobas® West Nile Virus (WNV) test kit image

Directly detect WNV, early in the infection lifecycle

The cobas® TaqScreen West Nile Virus Test is a Nucleic Acid Test (NAT) using real-time polymerase chain reaction (PCR) technology that amplifies and detects West Nile Virus (WNV) RNA in plasma from blood, organ and tissue donors. The test incorporates internal controls for monitoring test performance as well as the AmpErase® Enzyme to reduce potential contamination by previously amplified genetic material (amplicon).

Lab technician moving a blood sample

Automated real-time PCR amplification for early detection

  • Enables early detection of the virus in donors who may show no symptoms of disease
  • Ready-to-use reagents that do not require freezing
  • Helps streamline workflow and improve test results accuracy

Markedly reduce the risk of transfusion transmission

Designed to run on the cobas s 201 System, the cobas® TaqScreen West Nile Virus Test allows donor screening laboratories to maximize blood safety for blood banks, while reducing hands-on time with full automation at every step. Reverse transcription and amplification occur in the same reaction mixture, allowing for rapid and accurate blood test results.

Nurse administering an infusion

Intended use
 

The cobas® TaqScreen West Nile Virus Test, for use with the cobas s 201 system, is a qualitative in vitro test for the direct detection of West Nile Virus (WNV) RNA in human plasma.

This test is intended as a donor screening test to detect WNV RNA in plasma specimens from individual human donors, including donors of whole blood and blood components and other living donors. This test is also intended for use in testing plasma specimens to screen individual organ donors when specimens are obtained while the donor’s heart is still beating and in testing blood specimens from cadaveric (non-heart-beating) donors. This test is not intended for use on samples of cord blood.

Plasma from all donors may be screened as individual specimens. For donations of whole blood and blood components, plasma specimens may be tested in pools comprised of not more than six equal aliquots of individual specimens. For donations from cadaveric (non-heart-beating) organ and tissue donors, specimens may only be screened as individual specimens. This test is not intended for use as an aid in diagnosis.

Registration status

Canada-IVD, CE-IVD, US-IVD

Package inserts

Access package inserts through your country’s Roche Diagnostics Website.

cobas s 201 System image

Related system

cobas s 201 system

Discover efficiency, reliability and modular automation in the first multi-dye, nucleic acid amplification technology for blood and plasma.